1 der development for the topical treatment of onychomycosis.

2 deliver terbinafine to the nail bed to treat onychomycosis.

3 tion for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingern

4 talidium dimidiatum is a mold known to cause onychomycosis and dermatomycosis; however, it is an extr

5         All patients should be evaluated for onychomycosis because this may complicate psoriatic nail

6 ese infants and 1 health care worker who had onychomycosis had the same clone.

7 superficial infections such as keratitis and onychomycosis in immunocompetent humans; however, infect

8 AN2690), in development for the treatment of onychomycosis, inhibits yeast cytoplasmic leucyl-tRNA sy

9 with terbinafine for patients with suspected onychomycosis is more cost-effective than confirmatory t

10                                              Onychomycosis is the most common disease of the nail in

11 tion of TDT 067 for the topical treatment of onychomycosis is warranted.

12 cision analysis that compared the costs of 3 onychomycosis management algorithms based on recently pu

13     Primary outcomes included direct cost of onychomycosis testing and therapy and cost to avoid harm

14 ), which is currently in clinical trials for onychomycosis topical treatment.